Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.57 |
| ▸ | MEN1 | O00255 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | CASP1 | P29466 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MYB | P10242 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.51 |
| ▸ | MITF | O75030 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31237623 | 0.85 | MEN1 (0.78) | ALDH1A1MEN1KMT2ALMNACASP1 | |
| SCHEMBL4426684 | 0.81 | MAPK1 (0.61) | ALDH1A1MEN1KMT2ALMNACASP1 | |
| SCHEMBL31237204 | 0.80 | MAPK1 (0.65) | ALDH1A1MEN1KMT2ALMNACASP1 | |
| SCHEMBL4320562 | 0.80 | MAPK1 (0.65) | ALDH1A1MEN1KMT2ALMNACASP1 | |
| SCHEMBL4425522 | 0.79 | TUBB4A (0.67) | ALDH1A1MEN1KMT2ALMNACASP1 | |
| SCHEMBL31237961 | 0.79 | MYB (0.80) | L3MBTL1MYBMAPTGAARAB9A | |
| SCHEMBL8538963 | 0.79 | MYB (0.80) | L3MBTL1MYBMAPTGAARAB9A | |
| SCHEMBL4426296 | 0.78 | TUBB4A (0.66) | ALDH1A1HSD17B10MAPK1L3MBTL1MYB | |
| SCHEMBL4426920 | 0.78 | TUBB4A (0.66) | ALDH1A1HSD17B10MAPK1L3MBTL1MYB | |
| SCHEMBL13601123 | 0.78 | MAPK1 (0.58) | ALDH1A1MEN1KMT2ALMNACASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392683-B1 | SUBSTITUTED 4H-CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THEIR USE AS ANTICANCER AGENTS | CYTOVIA INC (US) | 2009-12-02 | — | — | EP | claimed |
| US-20060035925-A1 | SUBSTITUTED 4H-CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2006-02-16 | — | — | US | claimed |
| US-20030065018-A1 | Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-04-03 | — | — | US | claimed |
| EP-1392683-B1 | SUBSTITUTED 4H-CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THEIR USE AS ANTICANCER AGENTS | CYTOVIA INC (US) | 2009-12-02 | — | — | EP | disclosed |
| US-7053117-B2 | Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20060035925-A1 | SUBSTITUTED 4H-CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2006-02-16 | — | — | US | disclosed |
| US-20030065018-A1 | Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035925-A1 | SUBSTITUTED 4H-CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CASP4, CASP3, CASP7 | ALDH1A1 2014/4885MEN1 2444/4885KMT2A 2978/4885 |
| US-20030065018-A1 | Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP4, CASP5, CASP1 | ALDH1A1 774/4885MEN1 2109/4885KMT2A 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.